Health Update: Lionheart Health Launches Paid Study to Assess Structured Wellness Program’s Impact on Aging Biomarkers – What Experts Say

Lionheart Health, Inc. announced that enrollment is beginning for its Lionheart Klotho-Up Study, a longitudinal program designed to assess whether a structured wellness and bioelectric intervention program may help support key markers of healthy aging. The study is built around two core required elements: daily Klotho-favoring meals, supplements, and beverages, and BodStim Klotho-enhancing exercise performed two or three times weekly. Participants may also choose from optional supportive therapies like hyperbaric oxygen therapy, red light therapy, and pulsed electromagnetic field therapy, depending on availability and site offerings.

Howard Leonhardt, Executive Chairman and co-CEO of Lionheart Health, stated the company’s goal is to make a Klotho-supportive lifestyle and bioelectric wellness program more structured, measurable, and accessible. The study focuses on the protein Klotho, which is linked to muscle function, brain health, vascular health, and overall healthy aging biology. All participants must complete informed consent and agree to required baseline and one-year assessments covering muscle health, brain health, and immune health, including a 461 blood biomarker panel. Optional additional biomarker testing at 3 and 6 months, as well as an AI-enhanced MRI through CoreViva, may be available for deeper insights.

Enrollment is opening on a limited basis for qualified participants at licensed clinic locations. This is a subsidized paid registry study where patients pay $12.99 daily for delivered meals or can prepare their own following provided recipes. The BodStim EMS suit can be leased with an $890 down payment and $188 monthly payments. The 461 biomarker test costs $800 each for non-members and $463 for members, while Lionheart Health covers all required muscle, brain, and immunity health test assessments at baseline and one year. Optional AI-enhanced MRI scans will be covered by patients.

The study also supports Lionheart Health’s participation in XPRIZE Healthspan, where the company was named a Top 40 Milestone 1 awardee semi-finalist from over 600 registered teams worldwide. For selected candidates at certain outside the United States affiliated sites, biologic therapies may be available under separate, higher-risk informed consent. The study is intended for research, wellness, and health optimization purposes, with individual results potentially varying. More information is available at https://www.LionheartLongevity.com.